Dysregulated interleukin 6 expression produces a syndrome resembling Castleman's disease in mice.
about
Vironome of Kaposi sarcoma associated herpesvirus-inflammatory cytokine syndrome in an AIDS patient reveals co-infection of human herpesvirus 8 and human herpesvirus 6ASrc homology 2 domain-containing inositol-5-phosphatase and CCAAT enhancer-binding protein beta are targeted by miR-155 in B cells of Emicro-MiR-155 transgenic miceUpdate and new approaches in the treatment of Castleman diseaseEmerging treatments in Castleman disease - a critical appraisal of siltuximabInterleukin-6 blockade in ocular inflammatory diseasesKSHV infects a subset of human tonsillar B cells, driving proliferation and plasmablast differentiation.Transplantable myeloproliferative disease induced in mice by an interleukin 6 retrovirus.T-cell-dependent immunity and thrombocytopenia in rats infected with Plasmodium chabaudi.Kaposi sarcoma herpes virus-associated hemophagocytic syndrome complicated by multicentric castleman disease and kaposi sarcoma in a HIV-negative immunocompetent patient: an autopsy case.Multiple Myeloma and Chronic Lymphocytic Leukemia: Commonalities and Differences in Biology and Therapy.Potential use of recombinant human interleukin-6 in clinical oncology.The management of unicentric and multicentric Castleman's disease: a report of 16 cases and a review of the literature.A viral gene that activates lytic cycle expression of Kaposi's sarcoma-associated herpesvirus.Tocilizumab-induced remission of nephrotic syndrome accompanied by secondary amyloidosis and glomerulonephritis in a patient with rheumatoid arthritisAn interleukin-6-related systemic inflammatory syndrome in patients co-infected with Kaposi sarcoma-associated herpesvirus and HIV but without Multicentric Castleman diseaseImpact of interleukin-6 in hematological malignancies.The therapeutic potential of interleukin-6 hyperagonists and antagonists.Castleman's disease in the head of the pancreas: report of a rare clinical entity and current perspective on diagnosis, treatment, and outcomeClinical significance of interleukin (IL)-6 in cancer metastasis to bone: potential of anti-IL-6 therapies.Iron homeostasis and the inflammatory responseDistribution of human herpesvirus-8 latently infected cells in Kaposi's sarcoma, multicentric Castleman's disease, and primary effusion lymphomaHIV-associated multicentric Castleman diseaseCastleman's disease in childhood: report of three cases and review of the literatureCastleman's disease: from basic mechanisms to molecular therapeuticsExpression of a virus-derived cytokine, KSHV vIL-6, in HIV-seronegative Castleman's disease.Transgenic mouse model of AA amyloidosis.Clinical Manifestations of Kaposi Sarcoma Herpesvirus Lytic Activation: Multicentric Castleman Disease (KSHV-MCD) and the KSHV Inflammatory Cytokine Syndrome.Interleukin-6, but not interleukin-4, is expressed by Reed-Sternberg cells in Hodgkin's disease with or without histologic features of Castleman's diseaseRegulation of growth signalling and cell cycle by Kaposi's sarcoma-associated herpesvirus genes.HHV-8-encoded viral IL-6 collaborates with mouse IL-6 in the development of multicentric Castleman disease in miceTransgenic mice in the study of cytokine functionSequence analysis of Kaposi sarcoma-associated herpesvirus (KSHV) microRNAs in patients with multicentric Castleman disease and KSHV-associated inflammatory cytokine syndrome.Enhancement of in vitro and in vivo antigen-specific antibody responses by interleukin 11.A rare case of renal thrombotic microangiopathy associated with Castleman's disease.Castleman disease.Progenitor cell hyperplasia with rare development of myeloid leukemia in interleukin 11 bone marrow chimeras.The function of the soluble interleukin 6 (IL-6) receptor in vivo: sensitization of human soluble IL-6 receptor transgenic mice towards IL-6 and prolongation of the plasma half-life of IL-6.Inactivation of the IL-6 gene prevents development of multicentric Castleman's disease in C/EBP beta-deficient mice.[Castleman disease: unusual location of the chest].Kaposi's Sarcoma-Associated Herpesvirus Latency Locus Compensates for Interleukin-6 in Initial B Cell Activation.
P2860
Q24607716-669460DC-8326-4A34-BA27-2B45F8D37BFEQ24651080-0DAF7EE0-FB5B-4F5C-A7DB-D71ACA1E68D8Q26740703-F9294700-0474-4CD2-B3E1-FCF7BC355D5DQ26766554-42B1B644-660C-4777-83D2-F2A723B804F8Q27011357-3E1D2222-0BC9-470D-AEC4-4D71E9F6A261Q30433391-9948047C-2A2A-4450-BC9F-7BAD5476FF54Q33354120-F4891BB2-254B-453B-A644-2D21A8DD34AAQ33374203-10AB8F5E-D704-43FB-A4D6-784688DE5DFCQ33386458-5087C909-68B3-403F-BA74-AC3A4F0D7524Q33434182-84C44FD0-203E-4A24-AD28-4C6506AF56EEQ33497067-F8E1C7D2-739C-48D6-947F-9E02B7331AFFQ33544942-DECE05D9-DEBD-4A69-8AA0-C4517078AA4EQ33559699-7BC1AB86-79DC-44AD-B1AA-4D89A162445AQ33639788-42E7F690-8583-460C-8779-D5049D6C711CQ34157797-E9F17BA7-88DE-4C1B-B46D-8C9D7209BDC6Q34387624-A0B37CED-6906-456C-8E3E-238F2DF3028EQ34430168-D2A80DBA-30EA-4742-85E6-8CD332D84A96Q34585186-499089A0-C452-4EF1-81C4-12B9B8B4BE82Q35003674-8FEAEBBD-B5AA-4566-9D56-19AE9AAAAB94Q35024676-3D6C9CD1-A04F-46A8-A6BA-059CD17BBE9FQ35131811-04BD1970-FB66-46B6-9C53-09419CADA5F8Q35226470-C586827D-D35E-4A18-88F4-00B0D0111C97Q35560071-51BAE578-C6D2-4033-911E-7377292589C3Q35584575-3AD47AA8-C896-4768-9592-FCA01A613035Q35764989-9B52918D-F841-4223-BB29-A09D56BD4A38Q35786782-135C2A4F-2D88-42C8-94C1-EE4F76D1EA02Q35795414-FAF22477-1743-4660-8392-EE941D5FA6A4Q35831873-B1E7B3C8-28A7-402B-8117-ADA304D7B6E4Q35964857-43F88D41-056A-45C2-9639-B4B078D3CF83Q36018434-D7A0F833-FD99-4712-B91C-2EA77641301EQ36029215-2C805E18-7350-4740-894C-6FB69DBE2E4BQ36153930-D643F687-C008-42ED-933F-1F13AFFCC096Q36230765-33847A8B-E9B2-4265-9DA6-F5618512C7ECQ36275994-AFA7090E-AE57-48E3-A27B-7FC9C7978C43Q36297647-8E9C5767-332E-4E59-81D0-50B55CD8C9A7Q36362432-C6A9B241-DE77-48DB-973F-6BB87AC46602Q36366332-D2E7C366-F0EA-440D-97A2-BDC8355B28B4Q36367380-EF37FD1A-6852-401C-A31E-C178F643AD4CQ36372461-AA4FBF54-B5E6-4BDA-96EC-9442FD8BE0EFQ36524036-E02E539C-DB31-4257-9843-D9141842B4E6
P2860
Dysregulated interleukin 6 expression produces a syndrome resembling Castleman's disease in mice.
description
1990 nî lūn-bûn
@nan
1990 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1990 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1990年の論文
@ja
1990年論文
@yue
1990年論文
@zh-hant
1990年論文
@zh-hk
1990年論文
@zh-mo
1990年論文
@zh-tw
1990年论文
@wuu
name
Dysregulated interleukin 6 exp ...... g Castleman's disease in mice.
@ast
Dysregulated interleukin 6 exp ...... g Castleman's disease in mice.
@en
Dysregulated interleukin 6 exp ...... g Castleman's disease in mice.
@nl
type
label
Dysregulated interleukin 6 exp ...... g Castleman's disease in mice.
@ast
Dysregulated interleukin 6 exp ...... g Castleman's disease in mice.
@en
Dysregulated interleukin 6 exp ...... g Castleman's disease in mice.
@nl
prefLabel
Dysregulated interleukin 6 exp ...... g Castleman's disease in mice.
@ast
Dysregulated interleukin 6 exp ...... g Castleman's disease in mice.
@en
Dysregulated interleukin 6 exp ...... g Castleman's disease in mice.
@nl
P2093
P2860
P356
P1476
Dysregulated interleukin 6 exp ...... ng Castleman's disease in mice
@en
P2093
P2860
P304
P356
10.1172/JCI114749
P407
P577
1990-08-01T00:00:00Z